Myalepta (Metreleptin)

Metreleptin, the active ingredient in Myalepta, is a leptin analog presented as an injectable solution for subcutaneous use. It is indicated for patients with generalized or partial lipodystrophy, conditions characterized by deficient endogenous leptin, and works to restore normal regulation of appetite, energy expenditure, and metabolic homeostasis in affected individuals, often improving metabolic parameters.

GNH USA supplies Myalepta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality and regulatory compliance.

Myalepta (metreleptin) is used to treat metabolic disease associated with leptin deficiency, specifically lipodystrophy syndromes. - Generalized lipodystrophy: improves metabolic control, reduces hypertriglyceridemia, and helps normalize glucose levels. - Partial lipodystrophy: restores leptin levels, enhances insulin sensitivity, and supports lipid management. - Severe insulin resistance linked to lipodystrophy: aids glycemic management and reduces hepatic fat accumulation.

Myalepta may cause a range of adverse reactions. Monitoring patients for both common and serious events is recommended.

Common Side Effects: - Injection site pain or erythema - Headache - Nausea - Fatigue - Mild hypoglycemia - Transient abdominal discomfort

Serious or Rare Side Effects: - Anaphylactic reaction - Development of anti‑leptin antibodies leading to loss of efficacy - Severe hypersensitivity including rash or angioedema - Autoimmune phenomena such as lupus‑like syndrome - Pancreatitis

Before initiating therapy, clinicians should consider several safety measures. - Monitor triglyceride levels: assess baseline and follow‑up values regularly. - Assess liver function: perform hepatic enzyme testing periodically. - Screen for anti‑leptin antibodies: evaluate if clinical response diminishes. - Use with caution in patients with a history of severe hypersensitivity to protein therapeutics. - Avoid in individuals with active uncontrolled infection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metreleptin may interact with other agents that influence metabolic pathways.

Major Interactions (Avoid): - Concomitant use of other leptin analogs or recombinant hormones: may cause unpredictable immune responses. - Live vaccines: increased risk of altered vaccine efficacy.

Moderate Interactions (Monitor Closely): - Insulin or insulin secretagogues: enhanced glucose‑lowering effect may require dose adjustment. - Lipid‑lowering agents (e.g., fibrates, statins): monitor lipid profile for additive changes. - Hormonal therapies (e.g., estrogen, testosterone): observe for potential alterations in leptin signaling.